1. Protein Tyrosine Kinase/RTK
  2. PDGFR
  3. CP-673451


Cat. No.: HY-12050 Purity: 99.65%
Handling Instructions

CP-673451 is a potent and selective inhibitor of PDGFR with IC50s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

For research use only. We do not sell to patients.

CP-673451 Chemical Structure

CP-673451 Chemical Structure

CAS No. : 343787-29-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1 mL in DMSO USD 179 In-stock
Estimated Time of Arrival: December 31
5 mg USD 163 In-stock
Estimated Time of Arrival: December 31
10 mg USD 307 In-stock
Estimated Time of Arrival: December 31
50 mg USD 931 In-stock
Estimated Time of Arrival: December 31
100 mg USD 1260 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 9 publication(s) in Google Scholar

Top Publications Citing Use of Products

    CP-673451 purchased from MCE. Usage Cited in: FASEB J. 2016 Nov;30(11):3733-3744.

    Autocrine activation of receptor tyrosine kinases (RTKs) is required for induction of GLUT1 by TGF-b. Quantitative RT-PCR analysis of 10 ng/mL TGF-b1–stimulated GLUT1 expression (12 h post treatment) in AKR-2B cells in the presence of the PDGFR specific inhibitor, CP673451 (2 μM).

    CP-673451 purchased from MCE. Usage Cited in: Clin Cancer Res. 2019 Feb 1;25(3):1070-1086.

    Western blot analysis of co-IP of endogenous PDGFR or p-LATS1/2 with YAP from OV6+ UMUC3 or J82 cells without or with recombinant PDGF-BB (10 ng/ml) or CP-673451 (500 nM) for 4 days.

    CP-673451 purchased from MCE. Usage Cited in: Glia. 2020 Feb;68(2):345-355.

    Western blots of PDGFRα and NG2 in slices treated with CP673451 and Crenolanib for 9 days.

    View All PDGFR Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review


    CP-673451 is a potent and selective inhibitor of PDGFR with IC50s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

    IC50 & Target[1]


    10 nM (IC50)


    1 nM (IC50)

    In Vitro

    CP-673451 efficiently suppresses the PDGFR downstream signaling pathway. It inhibits phosphorylation of Akt, GSK-3β, p70S6, and S6 in A549 cells in a concentration-dependent manner. CP-673451 (0.0625-4 μM) significantly reduces the viability of NSCLC cell lines A549 and H1299 in a time- and concentration-dependent manner, with IC50s of 0.49 and 0.61 μM, respectively. CP-673451 (1, 4 μM) induces apoptosis in non-small-cell lung cancer cells. CP-673451 (25, 100, or 400 nM) is effective at inhibiting migration and invasion of NSCLC cells by suppression of lamellipodia formation[1]. CP-673451 and crenolanib show selective lethality toward cells with CA. U2OS cells treated with 1 to 4 μM CP-673451 or crenolanib show a ruffled cell surface as a sign for alterations of the cortical actin cytoskeleton. CP-673451 attenuates PDGF-BB-induced signaling, and significantly enhances the phosphorylation of PDGFR-β downstream effectors, Akt and MEK[2]. CP-673,451 (0.5 μM) regulates cell proliferation through mechanisms involving reduced phosphorylation of GSK-3α and GSK-3β. CP-673,451 impairs rhabdosphere-forming capacity in both RD and RUCH2 cultures[3]. CP-673,451 inhibits PDGFR-β in PAE-β cells with an IC50 value of 6.4 nM. Besides, CP-673,451 incubation in H526 and PAE-β cells results in an IC50 value of 1.1 μM against c-kit[4].

    In Vivo

    CP-673451 (20 mg/kg) leads to a medium suppression of tumor growth, while high-dose CP-673451 (40 mg/kg) strongly inhibits tumor growth in mice without significant weitht loss[1]. CP-673,451 (10, 33, and 100 mg/kg, p.o., b.i.d) inhibits the growth of Colo205 tumor in a dose-dependent manner, and similar tumor growth inhibition experiments completes on LS174T, H460, and U87MG xenografts, with no signs of morbidity or weight loss[4].

    Molecular Weight




    CAS No.





    Room temperature in continental US; may vary elsewhere.

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (239.52 mM)

    *"≥" means soluble, but saturation unknown.

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3952 mL 11.9760 mL 23.9521 mL
    5 mM 0.4790 mL 2.3952 mL 4.7904 mL
    10 mM 0.2395 mL 1.1976 mL 2.3952 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.75 mg/mL (6.59 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.75 mg/mL (6.59 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    Cell Assay

    Cell proliferation/viability is analyzed using the CyQuant proliferation assay. Pre-starved cells are treated every 24 hours with vehicle (dimethyl sulfoxide) or 0.5 μM CP-673,451 diluted in serum-reduced medium (1.5 % FBS) for 96 hours. The amount of nucleic acid present in lysed cells is normalized to the amount when treatment is initiated. Cell proliferation/viability in response to 300 ng/mL PDGF-CC is likewise analyzed, but cells are then kept in serum-free medium and treated twice during a 48-hour period.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    A subcutaneous A549 xenograft model in nude mice is used to evaluate the anticancer activity of CP-673451. Briefly, A549 cells are injected into the axillary regions of mice (2×106 cells/mouse). When the tumor volumes reach 70 mm3, the mice are randomly assigned to a control group and two CP-673451 groups (n=6 per group): low-dose (20 mg/kg) and high dose (40 mg/kg) groups (vehicle 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300). These animals are administered intraperitoneally with CP-673451 (20 or 40 mg/kg/day) or with vehicle. During the treatment period, the implanted tumors are measured by caliper once a day in a blind fashion. The animal body weights are also measured at the same time. The tumor volume is calculated. After treatment, the mice are killed, and the tumors are harvested and analyzed.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.


    Purity: 99.65%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    CP-673451CP673451CP 673451PDGFRPlatelet-derived growth factor receptorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name



    Applicant Name *


    Email address *

    Phone number *


    Organization name *

    Department *


    Requested quantity *

    Country or Region *



    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.:
    MCE Japan Authorized Agent: